|
Delayed
Sao Paulo
16:05:00 2026-09-04 EDT
|
5-day change | 1st Jan Change | ||
| 139.42 BRL | -0.24% |
|
-1.05% | -17.34% |
| 11:03am | Global markets live: Amazon, Lockheed Martin, Novartis, Audi, Eni… |  |
| 08:57am | BofA Upbeat on AstraZeneca's Camizestrant After US Approval Based on Serena-6 Trial Results | MT |
Company Valuation: AstraZeneca PLC
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 182,034 | 209,442 | 209,268 | 203,171 | 287,813 | 251,786 | - | - |
| Change | - | 15.06% | -0.08% | -2.91% | 41.66% | -12.52% | - | - |
| Enterprise Value (EV) 1 | 206,417 | 232,365 | 231,778 | 227,741 | 311,187 | 271,248 | 263,575 | 255,063 |
| Change | - | 12.57% | -0.25% | -1.74% | 36.64% | -12.83% | -2.83% | -3.23% |
| P/E | 1,469x | 64.1x | 35.4x | 29.1x | 28.4x | 20.9x | 18.3x | 15.9x |
| PBR | 4.24x | 5.65x | 5.39x | 5.02x | 5.96x | 4.67x | 4.15x | 3.52x |
| PEG | - | 0x | 0.4x | 1.6x | 0.6x | 1.1x | 1.3x | 1.1x |
| Capitalization / Revenue | 4.87x | 4.72x | 4.57x | 3.76x | 4.9x | 3.98x | 3.77x | 3.53x |
| EV / Revenue | 5.52x | 5.24x | 5.06x | 4.21x | 5.3x | 4.29x | 3.94x | 3.58x |
| EV / EBITDA | 27.2x | 25.2x | 17.1x | 13.6x | 16x | 12.2x | 10.8x | 9.52x |
| EV / EBIT | 20.8x | 17.4x | 15.9x | 13.5x | 16.8x | 12.9x | 11.3x | 9.98x |
| EV / FCF | 42.4x | 26.7x | 25.8x | 22.9x | 26.5x | 28.8x | 20.2x | 17.3x |
| FCF Yield | 2.36% | 3.75% | 3.88% | 4.36% | 3.78% | 3.47% | 4.95% | 5.77% |
| Dividend per Share 2 | 2.87 | 2.9 | 2.9 | 3.1 | 3.2 | 3.339 | 3.561 | 3.662 |
| Rate of return | 2.44% | 2.15% | 2.15% | 2.37% | 1.72% | 2.06% | 2.19% | 2.26% |
| EPS 2 | 0.08 | 2.11 | 3.81 | 4.5 | 6.54 | 7.777 | 8.891 | 10.22 |
| Distribution rate | 3,588% | 137% | 76.1% | 68.9% | 48.9% | 42.9% | 40.1% | 35.8% |
| Net sales 1 | 37,417 | 44,351 | 45,811 | 54,073 | 58,739 | 63,281 | 66,865 | 71,291 |
| EBITDA 1 | 7,586 | 9,237 | 13,580 | 16,691 | 19,476 | 22,156 | 24,309 | 26,782 |
| EBIT 1 | 9,928 | 13,350 | 14,534 | 16,928 | 18,478 | 21,073 | 23,284 | 25,554 |
| Net income 1 | 112 | 3,288 | 5,961 | 7,035 | 10,225 | 12,018 | 13,701 | 15,637 |
| Net Debt 1 | 24,383 | 22,923 | 22,510 | 24,570 | 23,374 | 19,462 | 11,788 | 3,277 |
| Reference price 2 | 117.51 | 135.16 | 135.02 | 131.05 | 185.60 | 162.34 | 162.34 | 162.34 |
| Nbr of stocks (in thousands) | 1,549,159 | 1,549,528 | 1,549,926 | 1,550,317 | 1,550,726 | 1,551,024 | - | - |
| Announcement Date | 2/10/22 | 2/9/23 | 2/8/24 | 2/6/25 | 2/10/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 32.72x | 11.9x | 24.26x | 0.6% | 1,024B | |
| 30.62x | - | - | 1.95% | 663B | |
| 32.73x | 7.6x | 15.8x | 2.67% | 453B | |
| 19.89x | 4.73x | 11.71x | 2.8% | 352B | |
| 22.72x | 5.84x | 14.51x | 2.7% | 304B | |
| 20.87x | 4.29x | 12.24x | 2.06% | 252B | |
| 27.66x | 7.14x | 13.15x | 2.31% | 236B | |
| 13.33x | 4.82x | 10.06x | 3.78% | 206B | |
| -46.14x | 6.65x | 25.95x | 2.18% | 187B | |
| Average | 17.16x | 6.62x | 15.96x | 2.34% | 408.71B | |
| Weighted average by Cap. | 24.05x | 7.99x | 17.80x | 1.95% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AZN Stock
- A1ZN34 Stock
- Valuation AstraZeneca PLC
Select your edition
All financial news and data tailored to specific country editions
